Long-term hormone use helps prostate cancer patients live longer

November 01, 2005

Doctors in Canada have discovered that treating high-risk prostate cancer patients with radiation therapy and adding hormone therapy for more than one year allows patients to live longer, have better control of their prostate specific antigen levels and lowers the rate of death specifically from prostate cancer, according to a study published in the November 1, 2005, issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO.

A total of 307 patients with a PSA level greater than 20 were split into two groups, both with a similar demographic of age, Gleason score and tumor stage. The first group had 151 patients receiving hormone therapy for less than 12 months (short term) and the second set had 156 patients receiving hormone therapy for more than 12 months (long term). Both groups were treated with hormone therapy in conjunction with external beam radiation therapy.

In the long-term hormone therapy group, 62.5 percent of patients showed a greater control over their PSA level, compared with 37 percent in the short-term group. The five-year overall survival rate was 87.5 percent for the long-term group and 75 percent in the short-term group. The chance of dying of prostate cancer was reduced from 18 percent to 6 percent in the long-term group.

"Other randomized trials have shown the benefit of combining radiation and hormone therapy in the treatment of prostate cancer. However, some of those reports appear to be restricted to patients with a high Gleason score," said Eric Berthelet, M.D., lead author of the study and a radiation oncologist at the BC Cancer Agency in Victoria, British Columbia, Canada. "This study proves that long-term hormone therapy used in consort with radiation therapy improves survival rates for high-risk patients, regardless of their Gleason score or tumor stage."
-end-
For more information on radiation therapy for prostate cancer, please visit www.rtanswers.org.

To arrange an interview with Dr. Berthelet or for a copy of "Long-Term Androgen Deprivation Therapy Improves Survival in Prostate Cancer Patients Presenting With Prostate-Specific Antigen Levels >20 ng/mL," please contact Nick Lashinsky at nickl@astro.org or 1-800-962-7876.

ASTRO is the largest radiation oncology society in the world, with more than 8,000 members who specialize in treating patients with radiation therapies. As a leading organization in radiation oncology, biology and physics, the Society is dedicated to the advancement of the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research and disseminating research results and representing radiation oncology in a rapidly evolving socioeconomic healthcare environment.

American Society for Radiation Oncology

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.